AFMD Short Information, Affimed N.V.

Twenty Trading Day Totals
Total Shorted Volume	2,789,689
Total Actual Volume	25,976,466

Averages
Average Short Volume	139,484
Average Short Percentage	47.75%

Is there a AFMD Short Squeeze or Breakout about to happen?

See the AFMD Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2022-06-30	2.75	2.77	2.795	2.695	653,948	53,547	45.6306
2022-06-29	2.78	2.81	2.82	2.695	600,760	55,272	61.3472
2022-06-28	2.96	2.78	2.96	2.75	1,208,236	222,113	74.8495
2022-06-27	2.71	2.92	2.975	2.71	1,251,199	150,936	55.1544
2022-06-24	2.77	2.71	2.865	2.71	5,447,126	167,917	55.9796
2022-06-23	2.76	2.84	2.85	2.7	1,099,118	190,444	69.7873
2022-06-22	2.5	2.73	2.8	2.46	1,094,600	133,075	41.6642
2022-06-21	2.55	2.56	2.655	2.54	1,023,806	99,228	37.4919
2022-06-16	2.32	2.32	2.35	2.23	728,336	68,001	35.8958
2022-06-15	2.32	2.37	2.4499	2.26	1,476,096	221,333	58.2725
2022-06-14	2.37	2.27	2.4093	2.25	790,620	135,670	48.4924
2022-06-13	2.47	2.37	2.5	2.34	981,346	138,477	48.9671
2022-06-09	2.89	2.74	3	2.73	649,794	92,792	42.1337
2022-06-08	2.94	2.92	3.065	2.88	1,140,450	203,576	56.4888
2022-06-06	3.13	2.82	3.18	2.79	1,501,783	182,151	38.6885
2022-06-03	3.11	3.1	3.24	3.035	1,157,873	96,472	33.1140
2022-06-02	3.12	3.1	3.1883	3.07	1,427,092	121,734	20.4131
2022-06-01	3.11	3.13	3.21	2.92	1,571,232	209,930	45.7520
2022-05-31	3.31	3.1	3.31	3.04	948,784	176,712	70.0713
2022-05-27	3.15	3.2	3.245	3.058	1,224,267	70,309	14.8939

Stock Information

Affimed N.V. Company Name:

AFMD Stock Symbol:

NASDAQ Market:

Get AFMD Alerts

News, Short Squeeze, Breakout and More Instantly...

AFMD - Affimed Establishes Scientific Advisory Board

Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology Scientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerg...
AFMD - Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-nega...
AFMD - Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022 AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and ...